What the business is, and whether it's a good one at a fair price.
Manufactures specialty chemicals for the Indian market, generating Rs 206.19 crore of revenue in FY26 and net profit of Rs 29.8852 crore at an EBITDA margin of 21.35%. The cost structure is materials-heavy, with raw inputs accounting for 48.1% of revenue, employees 15.7%, and other operating expenses 18.9%, leaving depreciation at 2.4% and capital expenditure at 4.5% of revenue. The filings do not break out individual product lines, but consolidated results include a share of profits from two associates, Peptech Biosciences and Titan Media, suggesting adjacent activity in biological products and media. The board has recommended a dividend of Rs 0.50 per equity share for FY26, and the equity was sub-divided 1:5 in February 2026, raising the share count from 82.64 lakh to 4.13 crore shares. The stock is listed on BSE only, and the recent filings are dominated by routine SEBI compliance, RTA confirmations, and quarterly financial results.
Measured from the filed financials, judged against its Specialty Chemicals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from TITAN BIOTECH LTD.'s filed financials and exchange disclosures
TITAN BIOTECH LTD. is a Chemicals & Petrochemicals company listed on BSE.
Yes. Over the trailing twelve months TITAN BIOTECH LTD. reported a net profit of ₹30 Cr on revenue of ₹206 Cr.
Yes. The dividend yield is 0.09% at the current price. It paid out 6% of its profit as dividend in FY26.
Effectively yes. Debt stands at 0.02× equity.
On trailing P/E, TITAN BIOTECH LTD. ranks 25 of 103 in Specialty Chemicals — cheaper than 77% of them, against an industry median of 23.4×. This is a position, not a valuation judgement.
On a typical session TITAN BIOTECH LTD. moves 2.14% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by TITAN BIOTECH LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
